Heerfordt's syndrome
ICD-10 D86.9 · ICD-11 4B20.Y.6

What Is the First-Line Treatment of Heerfordt's Syndrome?

Heerfordt's syndrome (coded under sarcoidosis, ICD-10 D86.9 / ICD-11 4B20.Y.6) requires structured first-line management that addresses both acutely ill presentations and cases of refractory or chronic disease requiring longer-term intervention.

Treatment Approach — Partial Overview

First-line management involves anti-TNF biologic therapy as a key intervention. Corticosteroid therapy is also an option for patients who are acutely and severely ill. The complete protocol — including agent selection, clinical decision points, and full sequencing — is available below.

Instant Access to Structured Evidence-Based Regimens

References

  1. In uveitis in general – including uveitis related to sarcoidosis – either infliximab or adalimumab has been useful in refractory cases.
  2. For patients who are acutely and severely ill, intravenous methylprednisolone for three days or anti-TNF therapy is recommended.
  3. Infliximab can also be used for chronic treatment or to “bridge” a patient until an immunosuppressive drug’s benefit becomes evident, typically in 2–3 months.
View source ↗